Our Signature Product
NOT ALL HYDROGELS ARE THE SAME
PAAG products, although often considered equal, have clear differences in composition, manufacturing and injection techniques as well as their ability to interact with surrounding tissues. These characteristics determine the safety and effectiveness of each hydrogel.
Arthramid Vet 2.5% PAAG
Arthramid Vet (AV) is a unique and patented hydrogel consisting of 97.5% sterile water and 2.5% polyacrylamide. This combination results in a gel similar to hyaluronic acid in structure and tissue compatibility, but with a superior and longer lasting effect, as it integrates into the joint itself and is non-degradable.
AV is elastic and viscous in nature, ideally suited for injection into the joints of animals providing an innovative and safe solution to veterinarians. Arthramid Vet is supplied in a sterile pre-filled 1ml syringe sealed with a Luer lock fitting.
AV is used to treat non-infectious causes of joint lameness in animals, including both early and late stages of osteoarthritis (OA). OA can be caused by traumatic injury or usual wear and tear which causes the joint to become inflamed. As the cartilage or cushion between the joints breaks down, pain, stiffness, and swelling develop, causing lameness.
Lameness remains the most common cause of reduced performance in the equine industry. In addition to pain reduction, treatment should also serve to arrest or slow down the progression of lesions allowing for disease modification. It is now well recognised that the OA disease process can start with the disease in the synovial membrane and that inflamed synovium is an essential component in the pathogenesis, with it almost always being present in cases of OA.
As part of the OA complex, the elastic and viscous nature of the synovial fluid is abnormally low. Furthermore, the synovial membrane becomes a source of inflammatory products which contribute to the progressive degradation of the joint over time.
Studies have shown disease-modifying effects as Arthramid Vet integrates into the synovial membrane, stabilising the joint capsule, and increasing elasticity, which, in turn, reduces the onset of synovitis and its harmful effects. The formation of rejuvenated synovium improves the nature of the synovial fluid within the joint itself.
Additionally, Arthramid Vet essentially causes a ‘cushion-like’ effect in the joint which allows for the preservation and/ or regeneration of the joint cartilage contributing to reducing the pain of synovitis and OA, and ultimately restoring the joint function.
World Safety Standards
• Danish manufacturer Contura International A/S exceeds world-class safety standards
• Human & Vet quality production with a 15-year track record
• ISO 9001, ISO 13485 Canadian ISO 13485 CMDCAS
Arthramid Vet 2.5% PAAG
2.5% PAAG exerts its effect via integration over 2-4 weeks within the joint capsule and adjacent soft tissues, through a combination of vessel in-growth, increased cell density, and molecular water exchange.
Next Generation; Multiple studies show up to 83% of horses respond positively to treatment.
Addresses Welfare Standards; Not simply a lubricant or painkiller. Its unique biomedical tissue scaffold technolgy helps heal and restore the joint to healthy function.
Made to Last; Clinical research shows Arthramid Vet is better and lasts longer with proven efficacy up to 2-years.
One of a Kind; Arthramid Vet’s unique and patented IL-X Cross-Linking Technology makes it the safest and most effective Polyacrylamide (PAAG) Hydrogel available.
- Addresses Welfare Concerns
- Long-lasting Beneficial Effects on the Symptoms of OA
- Unique IL-X Cross-Linking Technology enables optimal Tissue Integration
Get In Touch
Innovative Medical Solutions
Registered in New Zealand to: Innovative Medical Solutions Limited NZBN: 9429041325544, 32 Hill Road, Cambridge 3494, New Zealand. Registered pursuant to the ACVM Act 1997 Number A11596. See www.foodsafety.govt.nz for registration conditions.